Riccardo Canevari
Chief Executive Officer RadioPharm Theranostics
CEO since 2021, previously Chief Commercial Officer at Novartis, Advance Accelerator Applications (AAA)
Seminars
Friday 27th February 2026
Aligning Target Biology, Binder Format & Isotope with Tumor Treatment Paradigm
2:40 pm
- Discussing different pharmacokinetic properties of binders, including small molecule, peptide, mAbs and nanoparticles
- Evaluating need, niche, and efficacy when matching target biology to binder format and isotope
- Leveraging imaging to derisk and prove safety to curate a faster path to clinical proof of concept
- How do considerations around isotopes play into deal-making?
